Ultra-fast pencil beam scanning proton therapy for locally advanced non-small-cell lung cancers: Field delivery within a single breath-hold.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
09 2022
Historique:
received: 14 02 2022
revised: 03 06 2022
accepted: 22 06 2022
pubmed: 6 7 2022
medline: 4 10 2022
entrez: 5 7 2022
Statut: ppublish

Résumé

The use of motion mitigation techniques such as breath-hold can reduce the dosimetric uncertainty of lung cancer proton therapy. We studied the feasibility of pencil beam scanning (PBS) proton therapy field delivery within a single breath-hold at PSI's Gantry 2. In PBS proton therapy, the delivery time for a field is determined by the beam-on time and the dead time between proton spots (the time required to change the energy and/or lateral position). We studied ways to reduce beam-on and lateral scanning time, without sacrificing dosimetric plan quality, aiming at a single field delivery time of 15 seconds at maximum. We tested this approach on 10 lung cases with varying target volumes. To reduce the beam-on time, we increased the beam current at the isocenter by developing new beam optics for PSI's PROSCAN beamline and Gantry 2. To reduce the dead time between the spots, we used spot-reduced plan optimization. We found that it is possible to achieve conventional fractionated (2 Gy(RBE)/fraction) and hypofractionated (6 Gy(RBE)/fraction) field delivery times within a single breath-hold (<15 sec) for a variety non-small-cell lung cancer cases. In summary, the combination of spot reduction and improved beam line transmission is a promising approach for the treatment of mobile tumours within clinically achievable breath-hold durations.

Identifiants

pubmed: 35788354
pii: S0167-8140(22)04179-2
doi: 10.1016/j.radonc.2022.06.018
pii:
doi:

Substances chimiques

Protons 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

23-29

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of Interest The authors declare no conflict of interest.

Auteurs

Vivek Maradia (V)

Paul Scherrer Institute, Switzerland; ETH Zurich, Switzerland. Electronic address: vivek.maradia@psi.ch.

Steven van de Water (S)

Paul Scherrer Institute, Switzerland; Department of Radiation Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.

David Meer (D)

Paul Scherrer Institute, Switzerland.

Damien C Weber (DC)

Paul Scherrer Institute, Switzerland; University Hospital Zurich, Switzerland; University Hospital Bern, University of Bern, Switzerland.

Antony J Lomax (AJ)

Paul Scherrer Institute, Switzerland; ETH Zurich, Switzerland.

Serena Psoroulas (S)

Paul Scherrer Institute, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH